ROSELAND, N.J., Oct. 5 /PRNewswire/ -- Organon Pharmaceuticals Inc USA announces today the availability of Follistim(R) AQ (follitropin beta injection) 75 IU and 150 IU presentations in single-use 0.5 mL vials in pre-mixed solution, therefore eliminating reconstitution. Follistim(R) AQ is for subcutaneous and intramuscular injection used by patients undergoing assisted reproductive technology procedures, such as IVF and for the induction of ovulation to achieve pregnancy.
"Organon is pleased to provide patients and physicians a full range of fertility medications that can be tailored to meet individual needs. The addition of the Follistim(R) AQ vial in 75 IU and 150 IU presentations complements our existing fertility product portfolio of the Follistim(R) AQ Cartridge in 300 IU, 600 IU and 900 IU strengths which are designed to be used with the Follistim Pen(R)," said Michael Novinski, President, Organon Pharmaceuticals USA Inc. "Through our brands and supporting web sites, Organon is committed to providing integrated programs that meet patient's needs."
Organon continues to support patients and physicians in the fertility community with innovative products and educational resources. Patients can log on to http://www.fertilityjourney.com, an online resource that provides information, guidance and support as they undergo fertility treatments. Topics include: testing and diagnosis, therapy options and coping techniques. An online clinic locator assists with finding a local IVF clinic. Visitors to the site can also register to receive a free monthly e-newsletter and can order guidebooks packed with full-color diagrams, charts and support information.
Safety Information for Follistim(R) AQ Cartridge and Follistim(R) AQ Vial
-- Follistim(R) AQ Cartridge/Vial, like all gonadotropins, is a potent substance capable of causing mild to severe side effects including OHSS, with or without pulmonary or vascular complications.
-- Follistim(R) AQ Cartridge/Vial, should be prescribed only by physicians who are experienced in infertility treatment and physicians should advise their patients of treatment risks, including OHSS and multiple births.
Safety Information for Follistim(R) AQ Cartridge
-- Follistim(R) AQ Cartridge administered with Follistim Pen(R) delivers on average an 18% higher amount of follitropin beta compared to lyophilized preparations administered with a conventional syringe and needle. A lower dose should be considered when using Follistim(R) AQ Cartridge.
Organon, with shared head offices in Roseland, NJ, USA and Oss, The Netherlands creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary. Organon is the human health care business unit of Akzo Nobel. For more information about Organon, please go to http://www.organon-usa.com.
This report contains statements which address such key issues as Organon's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the "Outlook," should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.
For a more complete discussion of the risk factors affecting our business please see the Akzo Nobel Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company's website http://www.akzonobel.com.
* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
Contact: Fran DeSena Tracy Naden
Organon USA Inc. Fleishman Hillard Inc.
Organon Pharmaceuticals Inc USA